June 24-25, 2020


Kuala Lumpur, Malaysia

Conference Agenda

Explore your options to connect, learn and be inspired from our speakers

Keynote Session:

Meetings International -  Conference Keynote Speaker Prof. Jing Liu photo

Prof. Jing Liu

Professor, Director, Beijing Chaoyang District Maternal and Child Health Care Hospital, China

Title: Lung ultrasound-guided Bronchoalveolar Lavage to Treat Uninflated Pulmonary Disease of the Newborn


Prof.Dr.Jing Liu is the Director of Department of Neonatology and NICU,Beijing Chaoyang District Maternal and Child Health Care Hospital and the Neonatal Lung Ultrasound Training Base In China.He is good at neonatal intensive critical care, neonatal brain ultrasound and lung ultrasound. His academic positions include the Associate Chairman of Chinese Neonatologist Association and the Editorial members of more than 30 Chinese and English Journals. Dr.Liujing has published more than 300 papers, over 12 books and Chapters in Books, and has won 12 awards for science and technology of the government of China. Email:



Uninflated lung disease (UnILD) refers to atelectasis as a major pathologic lesion in the lung tissue, which mainly appearances of large area consolidations under lung ultrasound (LUS). Clinically,UnILDs primarily include pulmonary atelectasis of the newborn (PAN), severe pneumonia, and meconium aspiration syndrome (MAS).UnILDs are common diseases in newborn infants and the major reasons for acute respiratory deterioration, a prolonged hospitalization, and difficulties in weaning from mechanical ventilation.From January,2014 to October,2019,we conduct bronchoalveolar lavage (BAL) to treat neonatal UnILDs under the guidance of LUS and got excellent results. A mong of total of 745 patients, including PNA 201 cases, severe pneumonia 329 cases and MAS 215 cases. The results that Invasive ventilator use rate significant decreased(p<0.01),the duration required to receive invasive ventilator treatment significant reduced (p<0.01),the length of hospitalization significant decreased(p<0.01) and the hospitalization expenses significant decreased (p<0.05). All patients had stable vital signs during lavage and no adverse side effects were observed. So we concluded that under LUS monitoring, BAL has a significant effect on UnILDs.



Oral Session 1:

  • Pathogenesis of COPD | Drugs & Diagnostic Evolution of COPD | Pulmonary Infections & Treatment


Dr. Salil Bendre

Doctor,Head of Dept, Pulmonary Medicine , Nanavati Superspeciality Hospital Mumbai , India

Title: Optimizing Inhaled Drug Delivery


Dr Salil Bendre has completed his MBBS , MD in Pulmonary Medicine from a leading Medical College from Mumbai . Subsequently, he joined KJ Somaiya Medical College as a Lecturer .He continued Teaching and was then promoted as Prof and Head , Pulmonary Medicine . He has 17 years of Teaching Experience in Mumbai University. His interest is Interventional Pulmonary Medicine , Drug Resistant TB and HIV. He has presented papers on HIV and TB at National Conferences .He has conducted Respiratory Training workshops for over 1000 medical students .He is Currently Head of Dept of Pulmonary Medicine at Nanavati Superspeciality Hospital ,Mumbai. He has been featured in Television , Radio and Newspapers for Respiratory Talks and Interviews.



Background: Chronic obstructive pulmonary disease (COPD) is one of the most important reasons for hospitalization worldwide with high 30-day readmission rates. Although the prognostic significance of early readmission is not fully understood, they are often associated with poor outcomes including high mortality rates of 4%–19% at 30 and 365 days, respectively. Similarly, in acute exacerbations of COPD (AECOPD) cases receiving emergency department care, current status on lung function and cardiovascular comorbidities are considered as best predictors for both 30- and 90-day COPD readmission rates. Dual bronchodilator strategy with long-acting muscarinic antagonist (LAMA)/long-acting beta-agonists (LABA) is therefore recommended by GOLD (2019) in the postdischarge phase following an acute exacerbation.

Aim: To further assess the clinical impact of dual bronchodilators including glycopyrronium and arformoterol as home nebulization in the post-discharge phase of AECOPD, the current postapproval, observational study was conducted.

Materials and Methods: An observational, concurrent, and non-inferiority study with glycopyrronium and arformoterol home nebulizing solutions on patients with moderate and severe COPD was conducted at two centers in India. An estimated sample size of 40 patients involving moderate and severe COPD cases was factored for per-protocol analyses with P < 0.05 considered as statistically significant. A concurrent study analysis for the follow-up visit was conducted as per the principles of International Conference of Harmonization for Good clinical practice and Declaration of Helsinki while ensuring confidentiality during access of patient support registration sheets.



Meetings International - Respiratory Care 2020 Conference Keynote Speaker Dr. Gargi Maitra photo

Dr. Gargi Maitra

Consultant Pulmonologist

Title: Pathogenesis of COPD


Dr. Gargi Maitra, completed her MBBS from North Bengal University, stood 1st class 1st in her MBBS. She completed her MD in Pulmonary Medicine followed by Indian Diploma in Critical Care Medicine. She has worked as an Associate Editor for ‘Bronchoscopy in ICU, A Practical guide’ book. She has keen interest in critical care and interventional bronchoscopic procedures and has been actively involved in conducting and participating in various conferences at national level on Pulmonology and Bronchoscopy. She has presented cases in Lung India journal. She is an active member of Indian Chest Society (ICS), Indian Society of Critical Care Medicine (ISCCM), American College of Chest Physician (ACCP) and European Respiratory Society (ERS).



  1. Chronic Obstructive Pulmonary Disease (COPD) is a chronic inflammatory condition of the airways and alveoli leading to airflow limitation, giving rise to chronic cough, sputum production and breathlessness. Classically, tobacco exposure has been commonly linked to causation of COPD. However, many patients develop COPD without any history of tobacco exposure. Exposure to indoor pollution in the form of biomass fuel smoke or occupational exposure to smoke, may also contribute to development of COPD.

It is also known that pulmonary function reaches its peak (FEV1) at about twenty years of age and thereafter there is a gradual physiological decline in lung function. Due to any reason (like abnormal alveolar development in intrauterine life), if this peak lung function is not achieved in early adulthood, then a declining FEV1, at the same physiological rate, may give rise to early COPD symptoms and this process may further be hastened by smoke, tobacco exposure, infection etc. Infections like tuberculosis and systemic syndromes like Rheumatoid arthritis, HIV may also give rise to COPD symptoms.






Title: Pulmonary Infections & Treatment | Asthma Immunology & Medication| Immunodeficiency


As you aware, if temperature increases (Absence of  fever)after 31 degree Celsius , Warm sensitive neurons increase their firing rate and inhibit Cold sensitive neurons as core temperature increases. As temperature drops, the firing rate of Warm sensitive neurons decreases, reducing their inhibition, and Cold sensitive neurons which respond by increasing their firing rates.

On the contrary to increase of temperature, in fever the firing rate of Warm sensitive neurons decreases, the firing rate of Cold sensitive neurons increases as core temperature increases. inhibit warm sensitive neurons. The temperature increasing and decreasing controlled by the brain. The firing rate of Warm sensitive neurons and Cold sensitive neurons also controlled by the brain.



If the aim of   Cold sensitive neurons increasing their firing rates in hypothermia is to increase temperature, then the aim of Cold sensitive neurons  increasing their firing rates during fever is also to increase temperature.
How can we prove that W neurons decreases and C neurons increases in fever to protect the  life or organ?

If we ask any type of question related to fever by assuming that the Warm sensitive neurons decreases and Cold  neurons increases in fever to protect the  life or organ we will get a clear answer. If avoid or evade from this definition we will never get proper answer to even a single question

If we do any type of treatment  by assuming  that the Warm sensitive neurons decreases and Cold  neurons increases in fever to protect the  life or organ , the body will accept, at the same time body will resist whatever treatment to decrease temperature and blood circulation. No further evidence is required to prove The Warm sensitive neurons decreases and Cold  neurons increases in fever to protect the  life or organ.


Oral Session 2:

  • Pathogenesis of COPD | Drugs & Diagnostic Evolution of COPD | Pulmonary Infections & Treatment | Asthma Immunology & Medication| Immunodeficiency | Immunotherapy & Transplantation | Lungs Disease & Their Cause | Environmental & Occupational Lung Disease | Chronic Respiratory Diseases | Respiratory Pharmacology & Care | Acute Respiratory Distress Syndrome | Targeted Therapy for | Lungs Cancer | Cystic Fibrosis
Meetings International - Respiratory Care 2020 Conference Keynote Speaker Dr. Aloys Tan photo

Dr. Aloys Tan

Doctor, Advisor, Md

Title: Improving healthcare together by connecting the right people


Aloys Tan is a medical practitioner by profession with 40+ years of experience in the health care industry in the Netherlands and Asia. His interest lies in bridging the gap between fundamental research and its daily applications, particularly in the Healthcare realm in the European-Asia base. Between 1980 and 2000 he was chairman of the Pulmonology department of St. Joseph Hospital Veldhoven. Ever since, he has held various management positions in the areas of health care, social services and IT. Currently, Dr. Tan is partner and advisor in Landcent Europe Division and is instrumental in guiding Landcent’s regulatory initiatives in the region.


To be announced

Title: Outcome of Smear Positive Pulmonary Tuberculosis Patients with Acute Respiratory Failure on Non Invasive Ventilation in a Tertiary Care Hospital.


Dr Amit Sharma has completed his MBBS and MD in Pulmonary Medicine from Delhi University at age of 28. He is currently working as a Senior TB and Chest Specialist in NITRD for more than 9 years. He has guided the dissertations of Post Graduate Students and is closely associated with teaching and training activities in NITRD. Post PG experience is of more than 14 Years and has Case Reports published in International Journals as first and second author.



Pulmonary tuberculosis (PTB) coupled with Acute Respiratory Failure (ARF) usually heralds a dismal patient outcome1. Admission to the Intensive Care Unit (ICU) along with Invasive mechanical ventilation (IMV) in PTB patients is usually associated with very high mortality2. Non-invasive Ventilation (NIV) when applied early in such patients has the potential to prevent intubation and improve prognosis in terms of reduced morbidity and/or mortality 3. We conducted a prospective study in our Institute where NIV was applied to 35 patients with smear-positive PTB who had concurrent ARF. Fourteen patients (40%) improved on NIV and were later discharged on treatment (survivors). The remaining patients (60%) were candidates for IMV but none survived. Statistically significant predictors of mortality in our study were multiple courses of anti-tubercular treatment in the past, advanced disease as assessed radio-graphically, presence of leucocytosis, drug resistance and pH < 7.25. Our study is unique in the fact that it has addressed NIV in active PTB on which very scant literature is available. Our results indicate that a significant proportion of PTB patients with ARF may benefit from NIV based on astute and diligent patient selection and prompt institution of the procedure along with ATT and other supportive therapy. Our study also provides some tentative evidence that patients who fail NIV may not benefit from IMV. How much of this is due to the advanced lung disease and poorer metabolic status of the patient along with co-existent nosocomial infections needs to be elucidated by further studies.  



Title: The Reduction of Catheter-Related Blood Stream Infections through the Implementation of an Interdisciplinary Healthcare Team


Newark Beth Israel Medical Center, USA
Dartmouth Hitchcock Medical Center, USA
Florida Hospital Memorial Medical Center, Bert Fish Medical Center and Halifax Medical Center, USA


Hospital associated infections (HAIs) are defined by the CDC
as “infections that patients develop while they are receiving care in a health care setting for another condition with the estimated incidence of HAIs in the United States in 2012 being 4.5 per 100 patients” [1]. In 1950, the American Hospital. Association recommended that hospitals begin surveillance for HAIs due to a surge in infections caused by Staphylococcus aureus seen in postoperative patients. Today, bloodstream infections represent 14% [1] of all HAIs in the United States. Most of these bloodstream infections have been associated with central venous catheters (CVCs), which are defined by the National Healthcare Safety Network (NHSN) as “intravascular catheters that terminate at or close to the heart or in one of the great vessels which is used for infusion, withdrawal of blood, or hemodynamic monitoring” [2]. In
the US alone, the associated cost attributed to HAIs in 2012 was approximately 28–33 billion dollars [3]. HAIs continue to be a significant source of morbidity and mortality in the US Healthcare system. Bloodstream infections are divided
into two categories: central line associated bloodstream infec- tions (CLABSIs) and catheter-related bloodstream infections
 (CRBIs). The term CLABSI refers primarily to bloodstream infections in a patient with a central line in place within the 48-hour period before onset of the bloodstream infection that is not related to infection at another site. CRBIs, on the other hand, are bloodstream infections that require specific
laboratory testing to identify the catheter as the origin of the
infection; this testing is not a part of the criteria for a CLABSI.
It is estimated that 41,000 CLABSIs occur in U.S. hospitals
annually with an associated cost of $16,550.47 per infection
and an increased length of stay [4]. These infections have
been associated with an estimated inpatient mortality rate of
Hindawi Publishing Corporation
Journal of Critical Care Medicine
Volume 2015, Article ID 635939, 8 pages
2 Journal of Critical Care Medicine
12–25% [5]. For the purposes of surveillance, the definition
of a CLABSI is more practical, but it comes with its own
limitations. It has been noted by the Joint Commission that
this definition may overestimate the actual rate of infections
from central lines as opposed to another remote site.
In 2012, at Newark Beth Israel Medical Center (NBIMC),
a total number of 68 CLABSIs were recorded in the adult
population, and the resulting total represented a figure above
the national benchmark. This elevated number of infections
prompted the question, “what can we do as a teaching insti-
tution to reduce the rate of these bloodstream infections?” In
2011, in the Clinical Journal of Infectious Disease, Mermel
et al. made an important note that the pathogenesis of
catheter infections is a multifactorial process where both
intraluminal and extraluminal causes must be investigated
[6]. For this reason, we focused on multiple strategies targeted
at reduction. A multidisciplinary CLABSI prevention task
force was formed to examine our practices with regard to
central line insertion, maintenance, and removal, and to
implement a stringent policy that promoted tight adherence
to CDC practice bundle elements with a unified approach
that involved physicians and nurses actively monitoring each
hospital unit. The objective of this paper is to evaluate the
impact the implementation of a multidisciplinary task force
dedicated to appropriate central line insertion can have on
reducing rates of CLASBIs.



An experienced Public Health Expert; researcher, consultant, health manager and mentor with over twelve years of public health experience. Looking forward to inject these expertises in curriculum development, health systems strengthening,healthcare financing, consulting, program management to enhance societal growth.
Possess expertise in Sexual Reproductive Health, Malaria, HIV/AIDS, Nutrition, Maternal-Newborn-Child Health including quality management strategies; demonstrated leadership in partnership building, development of joint programs and programming.
Freelance Consultant specialized in program management and development-oriented research, including needs assessment and program evaluation; as well as program design, health systems strengthening/reforms, health systems and policy analysis, monitoring and evaluation, research and evaluations, strategy development and management, social marketing, project and program management and monitoring systems, in health sector reform, reproductive health.
Methodology and Management (results-based) programs: perfect control of project cycle, the results-based logical framework, annual program, budget, tenders selection, Consultant contract management.


The WHO Framework for Health Systems Performance Assessment recommends that decision makers at all levels need to quantify the variation in health system performance, identify factors that influence it and ultimately articulate policies that will archive better results in a variety of settings. The performance of sub-components of systems such as regions within countries or public health services also needs to be assessed. Health outcomes are a reflection of clinical quality/appropriateness of care and are co-produced by care providers and users. Their roles and responsibility differ but intertwine for the achievement of quality. While the provider is guided by professional and ethical policies, the user has needs and expectations to be met. Therefore, measuring users’ experiences as recipients of health services plays a significant role in assessing the delivery of quality healthcare. 
This study aimed at using patients’ experiences as a measure in assessing the quality of care rendered in the Regional Hospital Bamenda. 
A cross - sectional survey will was employed where patients who received care in the RHB were sampled to give a snapshot of the general opinion of patients who frequent the hospital. The PAHC instrument for in and out patients was used to collect data foranalysis in SPSS version 20. Regression analysis, 0.05 significance level, was used to calculate the correlation between the overall ratings of the hospital performance and the dimensions of care.
Majority of patients, 52% to 91.7%, had their various needs attained with the care they received though two of the expected care needs were unmet to a greater population. Most of patients revealed that they experienced a moderate (44%) and high (24%) global level of satisfaction with the quality of care rendered to them. The dimensions of care which had statistically significant associations with the overall hospital rating of quality of care received were identified as factors which positively influenced these patients’ experiences of care in the hospital. 
There is need for improvement in quality care provision to achieve better health outcomes.
(Key words: Health care delivery, Quality, Patients, Hospital days, patients’ experiences, health care services, doctors, nurses, Bamenda Regional Hospital).



Danica Sazdanić-Velikić, MD, PhD


Teaching assistant (PhD) at Department for Geriatrics

University of Novi Sad, Faculty of medicine,

Chief of Department for patients treated with radiotherapy,

Clinic for pulmonary oncology,

Institute for pulmonary diseases of Vojvodina, Sremska Kamenica, Serbia




Lung cancer is the leading cause of cancer death and is often diagnosed at a late stage. Due to that fact  long term survival rates are poor. Detecting the disease and initiating treatment at an early stage are important for improving survival. Low-dose computed tomography (LDCT) is strategy for lung cancer detection that has demonstrated promise in  purpose  to identify the presence of lung cancer in an individual that does not demonstrate any symptoms.

            Based on the results of the National Lung Screening Trial (NLST), NELSON trial, the US Preventive Services Task Force and NCCN guideline recommend annual lung cancer screening with CT. Annual screening for lung cancer with low-dose computed tomography (LDCT) is recommended in adults aged 55 to 80 years who have a 30 pack-year smoking history and currently smoke or have quit within the past 15 years.

           There could be risk for harm associated with LDCT screening include: radiation exposure, false negative and false-positive results, incidental findings, overdiagnosis. Patients with several comorbid conditions may be at greater risk.


Title: Noninvasive ventilation in prehospital settings


Mr Jithin has completed his Masters in Respiratory Care at the age of 25 years from Amrita University and currently doing his PhD in respiratory care at Srinivas University, India. He is the Academic Superintendent & Lecturer at Department of Respiratory Care, Prince Sultan Military College of Health Sciences under Ministry of Defense and Aviation, Kingdom of Saudi Arabia a premier alliead health sciences college in the Middle East. He is also the General Secretary of the prestigious Indian Association of Respiratory Care. He has published more than 14 papers in reputed journals and has been serving as an editorial board member of Indian Journal of Respiratory Care. 


The prehospital use of noninvasive ventilation (NIV) by emergency medical services is increasing. Applying NIV in the prehospital setting began to gain more attention in the late 1990s when the primary form of noninvasive positive pressure ventilation emerged as a substitute to endotracheal intubation. For the last several years, NIV has become the standard of care for acute cardiogenic pulmonary edema and exacerbation of chronic obstructive pulmonary disease patients in the prehospital setting. A remarkable number of studies demonstrate a reduction in mortality and intubation rates in comparison to standard care when NIV is initiated in the prehospital setting, though there is a lack of evidence to strongly recommend the use of prehospital NIV as a first choice. An in-depth understanding of the science and technological background of NIV machines and interfaces can help attending clinicians in the prehospital setting and thus enhance therapeutic effectiveness by maximizing patient comfort, safety, and stability. Selections of the patients, devices, and interfaces, as well as achieving good patient-ventilator synchrony, are the key aspects of a successful outcome.